New-onset paresthesias in inflammatory bowel disease

Gastroenterology. 2015 May;148(5):906-7. doi: 10.1053/j.gastro.2014.12.040. Epub 2015 Mar 27.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Anti-Inflammatory Agents / adverse effects*
  • Antibodies, Monoclonal / adverse effects*
  • Biopsy
  • Central Nervous System Diseases / chemically induced*
  • Central Nervous System Diseases / diagnosis
  • Central Nervous System Diseases / physiopathology
  • Crohn Disease / diagnosis
  • Crohn Disease / drug therapy*
  • Crohn Disease / immunology
  • Female
  • Gastrointestinal Agents / adverse effects*
  • Humans
  • Infliximab
  • Magnetic Resonance Imaging
  • Paresthesia / chemically induced*
  • Paresthesia / diagnosis
  • Paresthesia / physiopathology
  • Positron-Emission Tomography
  • Predictive Value of Tests
  • Remission Induction
  • Risk Factors
  • Sarcoidosis / chemically induced*
  • Sarcoidosis / diagnosis
  • Sarcoidosis / physiopathology
  • Spinal Cord / drug effects*
  • Spinal Cord / pathology
  • Spinal Cord / physiopathology
  • Time Factors
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

  • Anti-Inflammatory Agents
  • Antibodies, Monoclonal
  • Gastrointestinal Agents
  • Tumor Necrosis Factor-alpha
  • Infliximab

Supplementary concepts

  • Neurosarcoidosis